december 22, 2021

Ectin Research AB releases progress report on start of combined phase I / II study in urothelial bladder cancer

Ectin Research AB (“Ectin” or “the Company) announces it has submitted the ethics application required to initiate its Phase I / II clinical study. Upon approval of the ethics application, the phase I part of the study is expected to be initiated and patients can begin to be recruited during Q1 2022. Providing that patient recruitment goes as planned, the phase I part will end during Q4 2022. The Company announces too that an agreement has been concluded with Tamro AB for delivery of study drugs for the clinical study.

On September 1, 2021, Ectin announced that it had received approval from the Medical Products Agency to conduct a clinical phase I / II study of MFA-370 for the treatment of patients with metastatic urothelial bladder cancer. The first part of the study (phase I) will include 24 weeks of treatment of 10 patients with MFA-370 with an evaluation of safety and tolerability taking place after 6 weeks of treatment. If the results from the phase I study show that the treatment has an acceptable side effect profile, the phase II part of the study will be initiated provided funding is obtained.

Ectin has submitted the ethics application required to initiate the Phase I / II clinical trial. Subject to approval of the ethical application, the Company intends to start the phase I part of the combined phase I / II study in the first quarter of 2022 and, provided that patient recruitment proceeds as planned, to complete the phase I part during the fourth quarter of 2022.

The company also announces that an agreement has been concluded with Tamro AB to handle the logistics of study drugs for the study. Logistics services have been Tamro’s core business for 100 years.

Ectin Research CEO, Anna Sjöblom-Hallén: “We are extremely pleased to have concluded an agreement for the handling of study drugs for our clinical phase I / II study. Tamro has a solid reputation in the industry for a safe and secure distribution of medicines to healthcare. ”